Figure 2.
Dynamics of remaining allelic burden post-HCTD21and clonal association between initial AML and post-HCT relapse AML clone. Trace of mutations that are present at diagnosis and post-HCT (day 21) in (A) relapsed and (B) nonrelapsed patients. (C) Changes of remaining allelic burden from post-HCT (day 21) to relapse and 3 months post-HCT. Two patients relapsed at day 21 are excluded in this figure. (D) Comparison of allelic burdens in the initial AML clone and the post-HCT relapse AML clone.

Dynamics of remaining allelic burden post-HCTD21and clonal association between initial AML and post-HCT relapse AML clone. Trace of mutations that are present at diagnosis and post-HCT (day 21) in (A) relapsed and (B) nonrelapsed patients. (C) Changes of remaining allelic burden from post-HCT (day 21) to relapse and 3 months post-HCT. Two patients relapsed at day 21 are excluded in this figure. (D) Comparison of allelic burdens in the initial AML clone and the post-HCT relapse AML clone.

Close Modal

or Create an Account

Close Modal
Close Modal